+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immuno-oncology Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028

  • Report

  • 100 Pages
  • July 2022
  • Region: Global
  • Infinium Global Research
  • ID: 5642831
The report on the global immuno-oncology market provides qualitative and quantitative analysis for the period from 2022 to 2028. The report predicts the global immuno-oncology market to grow with a CAGR of nearly 18% over the forecast period from 2022-2028. The study on immuno-oncology market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2022 to 2028.

The report on immuno-oncology market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global immuno-oncology market over the period of 2022 to 2028. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global immuno-oncology market over the period of 2022 to 2028. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • An increase in the research and development in cancer immunotherapy will be driving the growth of the market
  • Increasing utilization in developed countries will drive market growth.

2) Restraints

  • High costs as compared to chemotherapy and radiotherapy will hamper the market growth.

3) Opportunities

  • The introduction of innovative and advanced treatment options creates new growth opportunities.

Research Methodology

A) Primary Research

The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include

1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/country managers
5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered

The global immuno-oncology market is segmented on the basis of type, targets, indication, and end users.

The Global Immuno-oncology Market by Type

  • Immune Cell Therapy
  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • Cytokines
  • Cancer Vaccines
  • Others

The Global Immuno-oncology Market by Targets

  • LAG-3
  • Anti-CTLA-4
  • MAGE-A3
  • VEGF
  • HDAC
  • Others

The Global Immuno-oncology Market by Indication

  • Malignant Tumors
  • Benign Tumors
  • Others

The Global Immuno-oncology Market by End Users

  • Hospitals
  • Specialty Clinics
  • Others

Company Profiles

The companies covered in the report include
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals
  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AstraZeneca PLC

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the immuno-oncology market.
2. Complete coverage of all the segments in the immuno-oncology market to analyze the trends, developments in the global market and forecast of market size up to 2028.
3. Comprehensive analysis of the companies operating in the global immuno-oncology market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
2.1. Immuno-oncology Market Highlights
2.2. Immuno-oncology Market Projection
2.3. Immuno-oncology Market Regional Highlights
3. Global Immuno-oncology Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Analysis of COVID-19 impact on the Immuno-oncology Market
3.4. Porter's Five Forces Analysis
3.5. Growth Matrix Analysis
3.5.1. Growth Matrix Analysis by Type
3.5.2. Growth Matrix Analysis by Targets
3.5.3. Growth Matrix Analysis by Indication
3.5.4. Growth Matrix Analysis by End Users
3.5.5. Growth Matrix Analysis by Region
3.6. Value Chain Analysis of Immuno-oncology Market
4. Immuno-oncology Market Macro Indicator Analysis
5. Global Immuno-oncology Market by Type
5.1. Immune Cell Therapy
5.2. Monoclonal Antibodies
5.3. Checkpoint Inhibitors
5.4. Cytokines
5.5. Cancer Vaccines
5.6. Others
6. Global Immuno-oncology Market by Targets
6.1. LAG-3
6.2. Anti-CTLA-4
6.3. MAGE-A3
6.4. VEGF
6.5. HDAC
6.6. Others
7. Global Immuno-oncology Market by Indication
7.1. Malignant Tumors
7.2. Benign Tumors
7.3. Others
8. Global Immuno-oncology Market by End Users
8.1. Hospitals
8.2. Specialty Clinics
8.3. Others
9. Global Immuno-oncology Market by Region 2022-2028
9.1. North America
9.1.1. North America Immuno-oncology Market by Type
9.1.2. North America Immuno-oncology Market by Targets
9.1.3. North America Immuno-oncology Market by Indication
9.1.4. North America Immuno-oncology Market by End Users
9.1.5. North America Immuno-oncology Market by Country
9.2. Europe
9.2.1. Europe Immuno-oncology Market by Type
9.2.2. Europe Immuno-oncology Market by Targets
9.2.3. Europe Immuno-oncology Market by Indication
9.2.4. Europe Immuno-oncology Market by End Users
9.2.5. Europe Immuno-oncology Market by Country
9.3. Asia-Pacific
9.3.1. Asia-Pacific Immuno-oncology Market by Type
9.3.2. Asia-Pacific Immuno-oncology Market by Targets
9.3.3. Asia-Pacific Immuno-oncology Market by Indication
9.3.4. Asia-Pacific Immuno-oncology Market by End Users
9.3.5. Asia-Pacific Immuno-oncology Market by Country
9.4. RoW
9.4.1. RoW Immuno-oncology Market by Type
9.4.2. RoW Immuno-oncology Market by Targets
9.4.3. RoW Immuno-oncology Market by Indication
9.4.4. RoW Immuno-oncology Market by End Users
9.4.5. RoW Immuno-oncology Market by Sub-region
10. Company Profiles and Competitive Landscape
10.1. Competitive Landscape in the Global Immuno-oncology Market
10.2. Companies Profiled
10.2.1. Bristol Myers Squibb Company
10.2.2. Novartis AG
10.2.3. F. Hoffmann-LA Roche Ltd.
10.2.4. Merck & Co., Inc.
10.2.5. Regeneron Pharmaceuticals
10.2.6. GlaxoSmithKline Plc.
10.2.7. Eli Lilly and Company
10.2.8. Fresenius Kabi AG
10.2.9. Pfizer Inc.
10.2.10. AstraZeneca PLC

Companies Mentioned

  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals
  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AstraZeneca PLC